Novel allosteric antagonists shed light on mglu 5 receptors and CNS disorders

Author： Spooren W.P.J.M.   Gasparini F.   Salt T.E.   Kuhn R.  

Publisher： Elsevier

ISSN： 0165-6147

Source： Trends in Pharmacological Sciences, Vol.22, Iss.7, 2001-07, pp. : 331-337

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies

By  

Current Neuropharmacology, Vol. 14, Iss. 5, 2016-06 ,pp. : 455-473

Bentham Science Publishers

Access to resources Recommend Favorite

Allosteric Modulators for mGlu Receptors

By  

Current Neuropharmacology, Vol. 5, Iss. 3, 2007-09 ,pp. : 187-194

Bentham Science Publishers

Access to resources Recommend Favorite

Novel heterocyclic compounds as mGlu5 antagonists: WO2009015897

By Doller Dario   Li Guiying   Brodbeck Robbin M   Thomsen Christian  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 3, 2010-03 ,pp. : 435-439

Informa Healthcare

Access to resources Recommend Favorite

In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [ 3 H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine)

By Anderson J.J.   Bradbury M.J.   Giracello D.R.   Chapman D.F.   Holtz G.   Roppe J.   King C.   Cosford N.D.P.   Varney M.A.  

European Journal of Pharmacology, Vol. 473, Iss. 1, 2003-07 ,pp. : 35-40

Elsevier

Access to resources Recommend Favorite

mGlu5 negative allosteric modulators: a patent review (2010 – 2012)

By Emmitte Kyle A  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 4, 2013-04 ,pp. : 393-408

Informa Healthcare

Access to resources Recommend Favorite